TRAIL及其受体在非小细胞肺癌中的表达

doi:10.3760/cma.j.issn.1673-422X.2016.03.002

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (3): 167-170.doi: 10.3760/cma.j.issn.1673-422X.2016.03.002

TRAIL及其受体在非小细胞肺癌中的表达

李东亮,李海燕,韩磊,段轶鋆,孙俊宁,张宁,苏文

030013 太原，山西省肿瘤医院胸外科（李东亮），康复一科（李海燕），免疫室（韩磊、段轶鋆、孙俊宁、张宁、苏文）

出版日期:2016-03-08 发布日期:2016-02-03
通讯作者: 苏文，Email: 13509731663@163.com E-mail:Email: 13509731663@163.com
基金资助:
山西省卫生厅科技攻关计划（2011048）

Expressions and clinical significances of TRAIL and its receptors in non-small cell lung cancer

Li Dongliang*, Li Haiyan, Han Lei, Duan Yijun, Sun Junning, Zhang Ning, Su Wen

Department of Thoracic Surgery, Tumor Hospital of Shanxi, Taiyuan 030013, China

Online:2016-03-08 Published:2016-02-03
Contact: Su Wen, Email: 13509731663@163.com E-mail:Email: 13509731663@163.com
Supported by:
Shanxi Provincial Health Department of Science and Technology Research Project (2011048)

摘要/Abstract

摘要： 目的研究肿瘤坏死因子相关凋亡诱导配体（TRAIL）及其受体TRAIL-R2和TRAIL-R4在非小细胞肺癌（NSCLC）中的表达及其意义。方法采用酶联免疫吸附试验（ELISA）检测79例NSCLC患者与80例正常人血清中TRAIL的表达水平，采用免疫组织化学法检测42例NSCLC组织及配对癌旁正常组织中TRAIL-R2和TRAIL-R4的表达水平。分析TRAIL、TRAIL-R2、TRAIL-R4与NSCLC患者临床病理特征的关系。结果 TRAIL在NSCLC患者血清中的表达明显低于正常人［(994.3±293.0)ng/ml∶(1 141.7±266.1)ng/ml］，差异具有统计学意义（t=3.29，P=0.00）。TRAIL的表达与NSCLC患者的临床分期（F=2.28，P=0.00）、分化程度（t=5.76，P=0.00）相关。TRAIL-R2在NSCLC组织中的阳性表达率为73.8%(31/42)，明显低于正常组织中的阳性表达率100.0%(42/42)（χ²=3.88，P=0.05），TRAIL-R2的表达与NSCLC患者的临床分期（χ²⁼27.89，P=0.00）、分化程度（χ²=9.50，P=0.00）相关。TRAIL-R4在NSCLC组织中的阳性表达率为81.0%(34/42) ，明显高于正常组织中的阳性表达率50.0%(21/42) （χ²=7.34，P=0.01），TRAIL-R4的表达与NSCLC患者的临床分期（χ²=17.82，P=0.00）、分化程度（χ²=4.47，P=0.03）相关。在NSCLC组织中，TRAIL-R4与TRAIL-R2的表达呈负相关（r=-0.67，P=0.01）。结论在NSCLC中，TRAIL、TRAIL-R2表达减少，TRAIL-R4表达增多，三者可能促进了NSCLC的发生发展，可为NSCLC临床治疗提供靶点。

关键词: 癌, 非小细胞肺, TNF相关凋亡诱导配体, 受体, TNF相关凋亡诱导配体

Abstract: Objective To investigation the expressions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors in non-small cell lung cancer (NSCLC) and their clinical significances. Methods The serum expression levels of TRAIL in 79 cases of NSCLC and 80 cases of normal subjects were detected by enzyme-linked immunosorbent assay (ELISA). The expressions of TRAIL-R2 and TRAIL-R4 in 42 cases of NSCLC and matched normal tissues were detected by immunohistochemistry. The relationships among TRAIL, TRAIL-R2, TRAIL-R4 and clinicopathologic features of NSCLC were analyzed. Results The expression of TRAIL in NSCLC patients was lower than that in normal human ［(994.3±293.0)ng/ml vs. (1 141.7±266.1)ng/ml, t=3.29, P=0.00］. The expression of TRAIL was closely correlated with clinical stage (F=2.28, P=0.00) and differentiated degree（t=5.76, P=0.00). The positive expression rate of TRAIL-R2 in NSCLC was 73.8% (31/42), significantly lower than that in the normal tissue 100.0% (42/42) (χ²=3.88, P=0.05). The expression of TRAIL-R2 was closely correlated with clinical stage (χ²=27.89, P=0.00) and differentiated degree (χ²=9.50, P=0.00). The positive expression rate of TRAIL-R4 in NSCLC was 81.0% (34/42), significantly higher than that in the normal tissue 50.0% (21/42) (χ²⁼7.34, P=0.01). The expression of TRAIL-R4 was also closely correlated with clinical stage (χ²=17.82, P=0.00) and differentiated degree (χ²=4.47, P=0.03). There was a negative correlation between the expression of TRAIL-R2 and TRAIL-R4 in NSCLC (r=-0.67, P=0.01). Conclusion The decrease of TRAIL and TRAIL-R2 and increase of TRAIL-R4 expression may promote the occurrence and development of NSCLC, and they may provide targets for clinical treatment of NSCLC.

Key words: Carcinoma, non-small-cell lung, TNF-related apoptosis-inducing ligand, Receptors, TNF-related apoptosis-inducing ligand

李东亮,李海燕,韩磊,段轶鋆,孙俊宁,张宁,苏文. TRAIL及其受体在非小细胞肺癌中的表达[J]. 国际肿瘤学杂志, 2016, 43(3): 167-170.

Li Dongliang, Li Haiyan, Han Lei, Duan Yijun, Sun Junning, Zhang Ning, Su Wen. Expressions and clinical significances of TRAIL and its receptors in non-small cell lung cancer[J]. Journal of International Oncology, 2016, 43(3): 167-170.

参考文献

［1］ Wiley SR, Schooley K, Smolak PJ, et al. Identification and chara-cterization of a new member of the TNF family that induces apoptosis［J］. Immunity, 1995, 3(6): 673-682. ［2］ Zerafa N, Westwood JA, Cretney E, et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies［J］. J Immunol, 2005, 175(9): 5586-5590. ［3］ Marini P, Schmid A, Jendrossek V, et al. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis［J］. BMC Cancer, 2005, 5: 5. DOI: 10.1186/1471-2407-5-5. ［4］ Arts HJ, De Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma［J］. Gynecol Oncol, 2004, 92(3): 794-800. DOI: 10.1016/j.ygyno.2003.11.054. ［5］ Zhuang L, Lee CS, Scolyer RA, et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosisinducing ligand［J］. Hum Pathol, 2006, 37(10): 1286-1294. DOI: 10.1016/j.humpath.2006.04.026. ［6］ Leithner K, Stacher E, Wurm R, et al. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy［J］. Lung Cancer, 2009, 65(1): 98-104. DOI: 10.1016/j.lungcan.2008.10.015. ［7］ Spierings DC, De Vries EG, Timens W, et al. Expression of TRAIL and TRAIL death receptors in stage Ⅲ non-small cell lung cancer tumors［J］. Clin Cancer Res, 2003, 9(9): 3397-3405. ［8］ Sanlioglu AD, Dirice E, Aydin C, et al. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells［J］. BMC Cancer, 2005, 5: 54. DOI: 10.1186/1471-2407-5-54. ［9］ Kim YJ, Lee SA, Myung SC, et al. Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ova-rian carcinoma cells by promoting activation of apoptosisrelated proteins［J］. Mol Cell Biochem, 2012, 359(1/2): 3343. DOI: 10.1007/s11010-011-0997-9. ［10］ Singh TR, Shankar S, Chen X, et al. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo［J］. Cancer Res, 2003, 63(17): 5390-5400. ［11］ Duiker EW, Meijer A, Van Der Bilt AR, et al. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carci-noma cells to rhTRAIL-induced apoptosis［J］. Br J Cancer, 2011, 104(8): 1278-1287. DOI: 10.1038/bjc.2011.84. ［12］ Bonomi P, Greco FA. Results of a phase 2 trial of HGS-ETR1(agonistic human monoclonal antibody to TRAIL receptor1)in subjects with relapsed/recurrent nonsmall cell lung cancer(NSCLC)［J］. Med Oncol, 2006, 23(2): 120-191.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[9]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[10]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[11]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[12]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[15]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.

TRAIL及其受体在非小细胞肺癌中的表达

Expressions and clinical significances of TRAIL and its receptors in non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价